Matches in Wikidata for { <http://www.wikidata.org/entity/Q91317678> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- Q91317678 description "article scientifique publié en 2019" @default.
- Q91317678 description "artículu científicu espublizáu en xineru de 2019" @default.
- Q91317678 description "scientific article published on 31 January 2019" @default.
- Q91317678 description "wetenschappelijk artikel" @default.
- Q91317678 description "наукова стаття, опублікована 31 січня 2019" @default.
- Q91317678 name "Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC" @default.
- Q91317678 name "Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC" @default.
- Q91317678 type Item @default.
- Q91317678 label "Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC" @default.
- Q91317678 label "Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC" @default.
- Q91317678 prefLabel "Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC" @default.
- Q91317678 prefLabel "Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC" @default.
- Q91317678 P1433 Q91317678-53F20E57-5EB6-40A1-8560-31D54580D5C3 @default.
- Q91317678 P1476 Q91317678-7EB1D976-96E7-4F85-9117-1ACBE81EFC09 @default.
- Q91317678 P2093 Q91317678-5D158B7B-5C96-4EDB-8237-224527C856DF @default.
- Q91317678 P2093 Q91317678-64673F7A-14DA-4CA3-A164-83E5730FC9F8 @default.
- Q91317678 P2093 Q91317678-7105B8B1-0279-4910-B51A-5F167D9602D8 @default.
- Q91317678 P2093 Q91317678-737EC248-E7D3-4EBD-9BD9-F5CBFC8ED937 @default.
- Q91317678 P2093 Q91317678-76C4CB24-70E8-423F-859A-F9A7D9180762 @default.
- Q91317678 P2093 Q91317678-87720700-771E-4167-9CB8-FA9E93BE23B6 @default.
- Q91317678 P2093 Q91317678-966BDD65-E12E-4F37-86B3-D5A7FFD58284 @default.
- Q91317678 P2093 Q91317678-B9366C5D-4DB1-4E5E-A2B1-B53277E547D8 @default.
- Q91317678 P2093 Q91317678-B95209AF-81F1-4700-B2AD-BB57A3F3E0EC @default.
- Q91317678 P2093 Q91317678-BB673588-0E80-449F-82EB-8C3D63DEAAB1 @default.
- Q91317678 P2093 Q91317678-D3CDC205-EF6E-4F49-B68F-EB3AE00710D8 @default.
- Q91317678 P2093 Q91317678-DDFD03AB-E8FE-4284-830E-EE14027DC28C @default.
- Q91317678 P2093 Q91317678-E6EDF1EE-B78F-495A-8520-81D696430730 @default.
- Q91317678 P304 Q91317678-47E9AF51-D9B1-42C0-86CE-9DEE64E8C682 @default.
- Q91317678 P31 Q91317678-F189CC56-0BA5-477C-ACF6-DA1194BD09C5 @default.
- Q91317678 P356 Q91317678-86D9BC50-8FAC-4659-B062-3275F4A2F611 @default.
- Q91317678 P433 Q91317678-833EAB8C-86CA-43E0-9582-022C0EBF141A @default.
- Q91317678 P478 Q91317678-D5D4F57C-E33F-4F89-9D53-4FF6540E812A @default.
- Q91317678 P50 Q91317678-0EBEC60C-8099-4185-BA25-BC9A90EC4B8A @default.
- Q91317678 P50 Q91317678-C6F9B45A-DFC5-46FB-976A-14EEE110B298 @default.
- Q91317678 P577 Q91317678-87FDE661-67EF-4D18-B1CE-B202C830010B @default.
- Q91317678 P698 Q91317678-3D1336F9-5661-4BCD-8137-12BD0617720F @default.
- Q91317678 P921 Q91317678-2AE8CED4-DA42-4179-9558-7E5E10FF11D8 @default.
- Q91317678 P921 Q91317678-91FC691E-8BC8-416E-A7F1-A84438D4F7BB @default.
- Q91317678 P921 Q91317678-D759A960-FA42-4D68-A0B7-A305D248E88E @default.
- Q91317678 P356 J.JTHO.2019.01.016 @default.
- Q91317678 P698 30711649 @default.
- Q91317678 P1433 Q2448056 @default.
- Q91317678 P1476 "Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC" @default.
- Q91317678 P2093 "Anne C Deitz" @default.
- Q91317678 P2093 "Dong-Wan Kim" @default.
- Q91317678 P2093 "Edward B Garon" @default.
- Q91317678 P2093 "Fabrice Barlesi" @default.
- Q91317678 P2093 "Gilberto de Castro" @default.
- Q91317678 P2093 "Gregory M Lubiniecki" @default.
- Q91317678 P2093 "Ji-Youn Han" @default.
- Q91317678 P2093 "Joo-Hang Kim" @default.
- Q91317678 P2093 "Mary Jo Fidler" @default.
- Q91317678 P2093 "Matthew A Gubens" @default.
- Q91317678 P2093 "Myung-Ju Ahn" @default.
- Q91317678 P2093 "Qiao Li" @default.
- Q91317678 P2093 "Veerle Surmont" @default.
- Q91317678 P304 "793-801" @default.
- Q91317678 P31 Q13442814 @default.
- Q91317678 P356 "10.1016/J.JTHO.2019.01.016" @default.
- Q91317678 P433 "5" @default.
- Q91317678 P478 "14" @default.
- Q91317678 P50 Q56605610 @default.
- Q91317678 P50 Q89006575 @default.
- Q91317678 P577 "2019-01-31T00:00:00Z" @default.
- Q91317678 P698 "30711649" @default.
- Q91317678 P921 Q13896859 @default.
- Q91317678 P921 Q3658562 @default.
- Q91317678 P921 Q420436 @default.